Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04068649 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Apr 24, 2025, no change to tracked fieldsv13-v14
  2. Primary completion date: Nov 18, 2024 to Nov 18, 2027
    • Study completion date: Nov 18, 2025 to Nov 18, 2027
    v12
  3. Re-verified, no change to tracked fieldsv11
  4. Primary completion date: Sep 9, 2024 to Nov 18, 2024
    • Study completion date: Sep 9, 2025 to Nov 18, 2025
    v10
  5. Study sites: 2 to 3v9
Show 7 earlier versionsHide 7 earlier versions
  1. Eligibility criteria shortened, about 6 wordsv8
  2. Collaborators shortened, about 4 wordsv7
  3. Re-verified, no change to tracked fieldsv6
  4. Study sites: 1 to 2v5
  5. Phase: Phase 3 to Phase 2v4
  6. Phase: Phase 2 to Phase 3
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 9, 2019 to Nov 18, 2019
    • Site details revised
    v3
  7. Start date: Sep 9, 2019 to Nov 9, 2019v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well single-fraction stereotactic body radiation therapy (SBRT) works when compared to standard radiation therapy in treating patients with cancer that has spread to other places in the body (metastatic). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
Trial Details
NCT Number NCT04068649
Lead Sponsor Roswell Park Cancer Institute
Conditions
(from sponsor)		 Metastatic Malignant Neoplasm
Related terms Neoplasm Metastasis
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov